[Piperacillin in in vitro-in vivo combination].
Launched two years ago, piperacillin is administered either alone or combined with other antibiotics. Broadening the antibacterial spectrum, looking for synergism and preventing the emergence of resistant mutants constitute a major preoccupation, especially in immunodepressed patients, and an indication for combined antibiotic therapy. The most effective combination, justified by in vitro tests, consists of a beta-lactam antibiotic and an aminoglycoside. In vitro studies have demonstrated an antagonistic effect between two beta-lactam antibiotics, and mutants have been isolated in vivo. The results obtained with the piperacillin-vancomycin combination are not as good as those obtained with previous combinations. The advent of new compounds, such as aztreonam, fluorinated quinolones and beta-lactamase inhibitors offers hopes of excellent results.
D000617:Aminoglycosides / Q000627:therapeutic use*; D000900:Anti-Bacterial Agents / Q000037:antagonists & inhibitors / Q000627:therapeutic use; D001424:Bacterial Infections / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D006801:Humans; D010403:Penicillin Resistance; D010878:Piperacillin / Q000627:therapeutic use*
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D010878:Piperacillin
La pipéracilline en association in vitro-in vivo.